Government Intensifies Efforts to Combat Breast Cancer in the UK

Over 1,000 individuals have enrolled in a groundbreaking trial aimed at revolutionising breast cancer treatment by reducing the duration of radiotherapy from three weeks to a mere five days. This initiative, supported by the government, could significantly decrease the number of hospital visits required for patients undergoing treatment, potentially sparing them up to ten trips.

Innovative Trial Promises Shorter Treatment Times

The FAST-Forward Boost trial, currently being conducted across 39 hospitals in the UK, seeks to evaluate the safety and efficacy of this accelerated radiotherapy regimen. The trial not only intends to shorten treatment times but also includes an additional targeted dose—known as a boost—to reduce the risk of cancer recurrence in patients. This significant advancement in breast cancer care comes at a time when Ashley Dalton MP, who is living with metastatic breast cancer, has been appointed as an adviser for the National Cancer Plan. Her role will focus on ensuring that patient experiences inform decisions related to cancer care.

Having stepped down from her position as Parliamentary Under-Secretary of State for Public Health and Prevention in March 2026, Ms Dalton is dedicated to managing her health while advocating for improvements in cancer care.

As Breast Cancer Awareness Month comes to a close, recent statistics reflect a notable increase in the number of women accepting their first breast screening invitation, with participation rising to 63.6%. Nevertheless, approximately 40% of women invited for their first screening do not attend.

Government Calls for Increased Screening Participation

The Secretary of State for Health and Social Care, Yvette Cooper, has urged women to seize this potentially life-saving opportunity when invited for screening. She emphasised the trial’s importance in utilising the UK’s renowned research capabilities to enhance cancer treatment within the NHS.

“This programme aims to radically shorten treatment times for breast cancer, supporting patients and ultimately saving lives,” Cooper stated. “The UK boasts some of the finest medical research and clinical expertise globally, and this trial exemplifies what can be achieved through collaboration.”

She further highlighted the necessity of incorporating the perspectives of those living with cancer into the broader discussion of cancer care, underlining the significance of Ms Dalton’s new advisory role.

Personal Commitment to Improving Cancer Care

In her remarks, Ashley Dalton MP expressed her gratitude for her appointment as the Government’s Cancer Advisor, highlighting the National Cancer Plan as a personal and professional milestone. “I am determined to ensure that the commitments outlined in the plan are effectively implemented,” she stated. “My experiences, both as a Health Minister and as someone living with metastatic breast cancer, will guide my efforts to support the goal that by 2035, three out of four people diagnosed with cancer will either be cancer-free or living well with the condition five years post-diagnosis.”

Professor Lucy Chappell, CEO of the National Institute for Health Research (NIHR) and Chief Scientific Adviser for the Department of Health and Social Care, reinforced the trial’s potential impact. “For two decades, the NIHR has funded high-quality research like the FAST-Forward Boost trial, which aims to transform patient care in the NHS,” she noted. “We understand the profound effects that breast cancer treatment can have on patients and their families, and initiatives like this are vital for identifying new, effective treatment options while minimising side effects.”

Future Outlook for Breast Cancer Treatment

If successful, the new treatment approach could alleviate travel burdens for patients, reduce time away from work and family, and free up NHS resources to treat more individuals. Furthermore, the government is collaborating with the NIHR and NHS England to implement artificial intelligence trials aimed at enhancing mammogram analysis. They are also partnering with Breast Cancer Now over the next three years to empower women to recognise signs of cancer and access reliable information and support post-treatment.

The National Cancer Plan outlines a comprehensive strategy to facilitate earlier cancer detection, improve treatment modalities, and ensure that those living with cancer receive optimal care and support. Professor Anna Kirby, Chief Investigator of the FAST-Forward Boost trial, expressed enthusiasm over reaching the milestone of 1,000 participants, noting the commitment shown by patients and clinical teams across the UK.

Encouraging Participation in Research Initiatives

“It is particularly heartening to see so many women, at a challenging time in their own lives, choosing to participate in research that could enhance future treatment options for women with breast cancer,” she remarked, extending gratitude to the participants for their invaluable contribution to advancing breast cancer care.

Rachael Franklin, Deputy Chief Executive at Breast Cancer Now, emphasised the importance of early diagnosis, noting that approximately 30% of female breast cancers in England are detected through screening, primarily at an early stage. “Maximising early diagnosis is crucial, as the likelihood of successful treatment increases significantly with early detection,” she added.

The FAST-Forward Boost trial aims to recruit a total of 4,830 participants by 2028, with follow-up assessments scheduled for five years, yielding results anticipated in 2033. The partnership with Breast Cancer Now, recently announced, supports the government’s Renewed Women’s Health Strategy, marking a significant step towards enhancing breast cancer care across the nation.

For further information or to arrange interviews with spokespeople and case studies from Breast Cancer Now, please contact press@breastcancernow.org.